Semaglutide vs Tirzepatide
A side-by-side research comparison of Semaglutide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Full name | Semaglutide (GLP-1 Receptor Agonist) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | FDA Approved |
| Mechanism | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 4,114 Da | 4,814 Da |
| Half-life | 7 days (168 hours) | 5 days (120 hours) |
| Bioavailability | High (SubQ ~89%), Moderate (oral ~1% with SNAC) | High (SubQ ~80%) |
| Typical dose | 0.25 mg → titrate up to 2.4 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.